Review ArticleOpen Access

Breakthrough Treatment for Mantle Cell Lymphoma

Volume 1 - Issue 4

Nahla A M Hamed*

Author Information Open or Close
- Professor of Hematology, Faculty of Medicine, Alexandria University, Egypt
*Corresponding author: Nahla A M Hamed, Professor of Hematology, Faculty of Medicine, Alexandria University, Egypt

Received: August 17, 2017; Published: September 01, 2017

DOI: 10.26717/BJSTR.2017.01.000322

To view the Full Article Peer-reviewed Article PDF

Abstract

MCL has a dismal prognosis (“the worst lymphoma to have”), with a median OS rate of 3 years only. Prognosis of limited stage disease is almost similar to that of stage lll MCL No curative therapy has been established so far. The US FDA granted breakthrough therapy designations to a bruton tyrosine kinase inhibitor, acalabrutinib in MCL patients who have previously received at least one line of therapy. Furthermore, the combination of bortezomib and a retinoid compound, fenretinide is synergistically cytotoxic against MCL lines and warrants further evaluation in vivo and in clinical trials. In addition, the combination of anti-Mcl-1 lipidoid nanoparticles with other forms of targeted therapy offers hope for reducing or replacing cytotoxic chemotherapy as standard treatment for MCL that over express Mcl-1.

Abbreviations : SOX11: Sry-related high-mobility-group box; MCL: Mantle Cell Lymphoma; NHL: Non-Hodgkin Lymphoma; OS: Overall Survival; CLL: Chronic Lymphocytic Leukemia; SLL: Small Lymphocytic Lymphoma; FL: Follicular Lymphoma; PLL: Prolymphocytic Leukemia; MIPI: MCL International Prognostic Index; FISH: Fluorescence In Situ Hybridization; MRD: Minimal Residual Disease; ASO-qPCR: Allele-Specific Oligonucleotide Quantitative Polymerase Chain Reaction; ISMCN: In situ mantle cell neoplasia; BM: Bone Marrow; siRNA: Short interfering RNA; ASCT: Autologous Stem Cell Transplantation; PR: Partial Response; R-HyperCVAD: rituximab + cyclophosphamide, doxorubicin, vincristine, dexamethasone alternating with methotrexate and cytarabine; R-CHOP: rituximab, cyclophosphamide, doxorubicin, Vincristine, and prednisone; R-CVP: rituximab, cyclophosphamide, vincristine, and prednisone; R-FC: rituximab, fludarabine, and cyclophosphamide; BR: bendamustine with rituximab, R-DHAP: rituximab, dexamethasone, cytarabine, and cisplatin; VcR-CVAD: bortezomib, rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; VR-CAP: bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone.